About Longdom Conferences

Longdom Conferences hosting 200+ leading international conferences and virtual events annually. It is instrumental in bringing together experts and learners from all over the globe for mutual growth and effective research-oriented discussions. The International Conference on Brain Disorders and Neurology is a leading platform dedicated to advancing the understanding and treatment of neurological disorders. Under the theme "NeuroFrontiers: Brain Health and Prevention" the conference aims to foster collaboration, innovation, and knowledge-sharing among professionals from diverse backgrounds.

Our mission is to bring together a global community of neurologists, neuroscientists, researchers, clinicians, and industry leaders to share the latest research, clinical practices, and technological advancements in the field. By creating an inclusive and collaborative environment, we strive to inspire new ideas, cultivate partnerships, and drive the future of brain health.

Why Attend?

This conference provides a unique platform for professionals to:

Learn from world-renowned experts through keynote presentations and interactive sessions.
Collaborate with peers and share knowledge on emerging trends and challenges.
Network with leading professionals, organizations, and innovators.
Discover new technologies, products, and services that are shaping the future of neurology.

Who Should Attend?

This conference is ideal for neurologists, neurosurgeons, neuroscientists, psychiatrists, psychologists, researchers, healthcare professionals, and anyone with an interest in brain health and neurological advancements.

Join us in Toronto to explore the frontiers of neuroscience, share your expertise, and help shape the future of brain health. We look forward to welcoming you to an unforgettable event!

Important Scientific Sessions:

1. Neurodegenerative Disorders

Neurodegenerative Disorders will cover recent advances in understanding and treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). It will focus on the pathophysiological mechanisms driving these diseases, the latest developments in biomarkers and imaging techniques, and novel therapeutic approaches. Participants will also explore the role of genetic and environmental factors in disease progression and the promise of emerging treatment modalities like immunotherapy and gene editing.

2. Neuroinflammation and Neuroimmunology

Neuroinflammation and Neuroimmunology will delve into the complex interplay between the immune system and the nervous system, focusing on diseases like Multiple Sclerosis and other neuroinflammatory disorders. It will highlight the latest research on immune mechanisms that contribute to neurological damage and the development of new immunomodulatory therapies. Discussions will also include biomarkers for early detection, neuroimmunology’s role in neurodegenerative diseases, and emerging therapeutic targets.

3. Stroke and Cerebrovascular Diseases

Stroke and Cerebrovascular Diseases will explore the latest advances in the management, treatment, and prevention of stroke and other cerebrovascular diseases. Topics will include innovations in acute stroke care, such as mechanical thrombectomy and thrombolysis, stroke rehabilitation techniques, and novel approaches to stroke prevention. It will also address advancements in neuroimaging technologies for better diagnosis and prognosis and the importance of public health initiatives in reducing stroke risk factors.

4. Epilepsy and Seizure Disorders

Epilepsy and Seizure Disorders focus on the mechanisms underlying epilepsy and seizure disorders, along with advancements in diagnosis and treatment. It will cover new research on the molecular and cellular processes involved in epileptogenesis, innovations in anti-epileptic drug development, and surgical options for drug-resistant epilepsy. Additionally, the session will discuss neuromodulation techniques, such as deep brain stimulation, and address the psychosocial aspects and quality of life in epilepsy management.

5. Traumatic Brain Injury and Concussion

The session on traumatic brain injury (TBI) and concussion will explore the latest research on the pathophysiology, diagnosis, and treatment of TBI, including sports-related concussions. It will highlight advances in imaging technologies, biomarkers for assessing injury severity, and therapeutic strategies for acute management and long-term recovery. Emphasis will also be placed on the cognitive, behavioral, and psychological outcomes following TBI and the development of rehabilitation approaches to improve patient outcomes.

6. Neuropsychiatry and Behavioral Neurology

Neuropsychiatry and Behavioral Neurology will explore the neurological underpinnings of psychiatric and behavioral disorders, such as depression, anxiety, schizophrenia, and cognitive impairment. It will feature discussions on the latest neuroimaging techniques, biomarker discoveries, and neuropsychological assessments used in diagnosing and treating these conditions. The session will also examine therapeutic approaches, including cognitive-behavioral therapy, pharmacological treatments, and neuromodulation techniques, to enhance patient care.

7. Pediatric Neurology

Pediatric Neurology will focus on neurological disorders affecting children, such as pediatric epilepsy, neurodevelopmental disorders, and neurometabolic diseases. It will highlight the latest diagnostic tools, genetic testing, and therapeutic interventions, including novel drugs, surgical treatments, and neurorehabilitation strategies. The session will also discuss the unique challenges of managing neurological disorders in the pediatric population, including early detection, family support, and the long-term impact on cognitive and motor development.

8. Neuro-oncology

This session will cover the latest advances in the diagnosis, treatment, and management of brain tumors and other cancers affecting the nervous system. Topics will include molecular profiling of tumors, targeted therapies, immunotherapy, and advances in neuroimaging for better tumor visualization and monitoring. It will also explore innovative surgical techniques, such as minimally invasive and robotic-assisted surgeries, and discuss the role of multidisciplinary care in improving patient outcomes.

9. Neuromuscular Disorders

Neuromuscular Disorders will focus on diseases affecting the muscles and the nerves controlling them, such as muscular dystrophy, myasthenia gravis, and peripheral neuropathies. It will cover recent advances in genetic research, novel diagnostic tools, and therapeutic interventions, including gene therapy, immune therapies, and rehabilitation techniques. The session will also discuss the role of multidisciplinary care and the impact of these disorders on quality of life.

10. Advances in Neurosurgery

This session will highlight the latest technological advancements and innovations in neurosurgery, including minimally invasive surgery, robotic-assisted techniques, and image-guided surgery. It will cover the application of these techniques in treating various brain disorders, such as tumors, aneurysms, and epilepsy. Discussions will also focus on the ethical considerations in neurosurgery, the integration of artificial intelligence and machine learning, and the future of neurosurgical education and training.

11. Neurorehabilitation

Neurorehabilitation will explore current approaches to rehabilitation for patients recovering from neurological disorders, such as stroke, traumatic brain injury, and neurodegenerative diseases. It will highlight advancements in therapeutic strategies, including neuroplasticity, virtual reality, robotic-assisted rehabilitation, and artificial intelligence. The session will also focus on the development of personalized rehabilitation programs, the use of digital health tools, and the importance of a multidisciplinary approach in enhancing patient recovery and quality of life.

12. Brain-Machine Interfaces and Neurotechnology

This session will delve into the rapidly evolving field of brain-machine interfaces (BMIs) and neurotechnology, exploring their applications in restoring motor function, communication, and sensory feedback in patients with neurological impairments. It will highlight the latest developments in neural engineering, neuroprosthetics, and non-invasive brain stimulation techniques. Ethical and privacy concerns, as well as the future potential of these technologies in both clinical and non-clinical settings, will also be discussed.

13. Cognitive Neuroscience and Neuropsychology

The session on Cognitive Neuroscience and Neuropsychology will focus on the mechanisms underlying cognitive functions such as memory, attention, and decision-making, and how these are affected in neurological disorders. It will cover the latest advances in neuroimaging, neuropsychological assessment, and cognitive rehabilitation techniques. The session will also discuss the role of neuroplasticity in recovery from brain injury and the development of new therapeutic strategies to improve cognitive outcomes.

14. Neuropharmacology and Drug Development

Neuropharmacology and Drug Development will cover the latest advancements in neuropharmacology, focusing on the discovery and development of new drugs for treating neurological and neuropsychiatric disorders. It will include discussions on novel therapeutic targets, clinical trials, and innovative drug delivery systems. The session will also highlight the challenges in translating basic neuroscience research into effective therapies and the potential of precision medicine in tailoring treatments to individual patients.

15. Neurogenetics and Genomic Medicine

Neurogenetics and Genomic Medicine session will explore the role of genetics in the development of neurological disorders and the potential of genomic medicine to transform diagnosis and treatment. It will cover advances in gene editing technologies, such as CRISPR, and their application in treating genetic neurological diseases. Discussions will also focus on the ethical implications of genetic interventions, personalized medicine, and the future of gene-based therapies in neurology.

Market Analysis Report:

The global neurology clinical trials market was valued at USD 5,235.8 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2030. This growth is primarily driven by the increasing prevalence of neurological diseases, such as dementia, stroke, and peripheral neuropathy, as well as rising investments in research and development for neurological studies.

The market experienced significant disruption during early 2020 and 2021 due to the global COVID-19 pandemic, as most clinical trials shifted focus to the treatment and diagnosis of COVID-19. However, with the decline in COVID-19 cases due to widespread vaccination efforts, clinical studies in other therapeutic areas, including neurology, began to recover. Notably, several new studies for neurological disorders were launched in 2022. For example, the study "SGT-53 in Children with Recurrent or Progressive CNS Malignancies" began in June 2022, and the "GB5121 in Adult Patients with Relapsed/Refractory CNS Lymphoma" study started in May 2022. The resurgence of such studies is expected to drive market growth.

The global burden of neurological diseases has heightened interest from sponsors and investors in funding clinical studies. Substantial financial support has been allocated for neurological trials in recent years. For instance, in March 2022, researchers from Brown University, New York University, and the University of Rochester received USD 16 million from the National Institutes of Health (NIH) to support Alzheimer’s disease research. Similar initiatives are anticipated to further boost market growth.

The aging global population has also contributed to the rise in neurological disorders. According to the World Health Organization (WHO), the number of people aged 60 and above reached over 1.4 billion in 2020 and is expected to increase to 2.1 billion by 2050. This demographic trend is a key factor in the growing prevalence of neurological conditions such as Alzheimer’s disease, stroke, and Parkinson’s disease. Alzheimer’s disease alone affects over 50 million people worldwide, while Parkinson’s disease impacts 10 million. The high prevalence of these conditions is driving demand for research, which is likely to stimulate market growth.

To improve patient accessibility, a significant number of neurological clinical trials have transitioned to decentralized models. For example, in August 2020, Firma Clinical Research partnered with C2N Diagnostics to initiate a decentralized clinical trial for Alzheimer’s disease diagnosis. The increased adoption of such trials is expected to enhance participant engagement, further propelling market growth.

abstracts@longdom.com

finance@longdom.com

support@longdom.com

Speakers Interview

Abstracts enquiry

Registration enquiry

Contact Enquiry

Phone

WhatsApp

Useful Links

News

Determining pathways that link brain, body, lifestyle and mental health

Joint inference of discrete and continuous factors captures variability across and within cell types

Mapping connectivity and network alterations in youth depression by functional brain imaging

Newsletter